The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
7th European CAR T-cell Meeting congress coverage
Catch up with our live social media coverage of lymphoma and chronic lymphocytic leukemia from the 7th European CAR T-cell Meeting
CONGRESS | #CART25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) February 6, 2025
Pere Barba @UABBarcelona presented results from a phase II study of rapcabtagene autoleucel in patients with R/R DLBCL.
N=63, ORR was 88.3%, CRR was 65%. Median DoR was 15.2 months, median PFS was 11.9 months, 12-months OS was 83%. The safety… pic.twitter.com/PbQnY1Vy5L
CONGRESS | #CART25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) February 6, 2025
Tanya Siddiqi @cityofhope shares insights of using CAR T-cell therapy for patients with #CLL using encouraging data from the phase I/II TRANSCEND CLL 004 trial of lisocabtagene maraleucel combined with ibrutinib in patients with R/R CLL/SLL.… pic.twitter.com/8LsrQhO72h
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
